Pier Capital LLC Grows Stock Position in Guardant Health, Inc. (NASDAQ:GH)

Pier Capital LLC lifted its stake in Guardant Health, Inc. (NASDAQ:GH) by 45.4% during the fourth quarter, Holdings Channel reports. The institutional investor owned 230,280 shares of the company’s stock after acquiring an additional 71,851 shares during the quarter. Pier Capital LLC’s holdings in Guardant Health were worth $7,035,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. R Squared Ltd purchased a new position in Guardant Health in the fourth quarter valued at $26,000. SBI Securities Co. Ltd. purchased a new position in shares of Guardant Health in the 4th quarter valued at about $43,000. Kimelman & Baird LLC acquired a new position in Guardant Health in the 4th quarter worth about $58,000. Quantbot Technologies LP acquired a new position in Guardant Health in the 4th quarter worth about $80,000. Finally, Jones Financial Companies Lllp boosted its position in Guardant Health by 43.5% during the fourth quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company’s stock worth $82,000 after purchasing an additional 817 shares in the last quarter. 92.60% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Stifel Nicolaus boosted their price objective on Guardant Health from $45.00 to $53.00 and gave the company a “buy” rating in a research report on Friday, February 21st. The Goldman Sachs Group boosted their price target on shares of Guardant Health from $49.00 to $56.00 and gave the stock a “buy” rating in a report on Friday, February 21st. Scotiabank increased their price objective on shares of Guardant Health from $47.00 to $52.00 and gave the company a “sector outperform” rating in a report on Monday, February 24th. JPMorgan Chase & Co. boosted their target price on shares of Guardant Health from $50.00 to $55.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. Finally, Barclays began coverage on shares of Guardant Health in a research report on Thursday, January 23rd. They set an “overweight” rating and a $60.00 price target for the company. Twenty investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Guardant Health currently has a consensus rating of “Buy” and an average target price of $48.40.

Guardant Health Price Performance

GH stock opened at $46.74 on Tuesday. Guardant Health, Inc. has a 1 year low of $15.81 and a 1 year high of $50.89. The firm has a market capitalization of $5.77 billion, a PE ratio of -13.13 and a beta of 1.50. The business has a 50 day simple moving average of $44.02 and a 200-day simple moving average of $33.79.

Guardant Health (NASDAQ:GH) last issued its earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.15). The company had revenue of $201.81 million during the quarter, compared to analyst estimates of $192.50 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. On average, equities research analysts expect that Guardant Health, Inc. will post -2.9 EPS for the current year.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.